Skip to main content
Premium Trial:

Request an Annual Quote

International Therapeutics Licenses RNAi Quantification Product to Rosetta

NEW YORK, Sept. 28 (GenomeWeb News) - International Therapeutics has granted to Rosetta Inpharmatics a worldwide nonexclusive license to its ProxiQuant technology for research and development applications, IT said today.


ProxiQuant is an enzymatic application that enables stoichiometric generation of surrogate DNA targets from primary RNAi molecules in biological samples, IT said. As opposed to RT-PCR, ProxiQuant uses ligases to create larger DNA molecules from smaller RNAi, which can then be quantified using several methods.


Financial details of the agreement were not disclosed.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.